share_log

TC BioPharm | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)

SEC announcement ·  Feb 14 14:39
Summary by Moomoo AI
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a shared voting and dispositive power over 105,938 American Depositary Shares of TC BioPharm (Holdings) PLC, which represents 9.99% of the class. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as the managing member of Armistice Capital, are deemed to beneficially own the shares held by the Master Fund. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, indicating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing was certified by Steven Boyd on February 14, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more